Hormone replacement therapy and endometrial cancer:
After over 13 years of follow-up since the WHI started, it was found that endometrial cancer risk was lowered by 35%. (10).
U.S. Food and Drug Administration (FDA) advises on hormone replacement therapy:
FDA indications for hormone replacement therapy:
FDA recommends that only FDA-approved hormone therapies be used for the treatment of vasomotor symptoms such as hot flashes and vaginal or vulvar atrophy, and not solely for the prevention of heart disease or osteoporosis. The FDA advises that hormonal therapy be used at the lowest dosage able to control symptoms for the shortest period of time. Hormonal therapy may be considered in women with osteoporosis unable to take other non-hormonal osteoporosis medications. (3)
